Jin‐Ji Yang

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial.

Yi‐Long Wu, Wen‐Zhao Zhong, Qun Wang et al. · Journal of Clinical Oncology · 2020 · 61 citations

N1-n2 Nsclc, Surgical Oncology, Oncology +12

Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR -Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib

Jin‐Hyoung Kang, Hua‐Jun Chen, Zheng Wang et al. · Journal of Thoracic Oncology · 2017 · 58 citations · Full text

Pathology, Cancer Biology, Tumor Biology +16

Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies

Zhong‐Yi Dong, Chao Zhang, Yufa Li et al. · Journal of Thoracic Oncology · 2017 · 56 citations

Cancer Immunosurveillance, Medicine, Immunology +9

First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial

Si‐Yang Maggie Liu, Hai‐Yan Tu, Xue‐Wu Wei et al. · Nature Medicine · 2023 · 56 citations

Patient-centric Phase 2, Medicine, Bronchial Neoplasm +8

Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial

Yichen Zhang, Zhihong Chen, Xu‐Chao Zhang et al. · EBioMedicine · 2019 · 45 citations · Full text

Medicine, Pharmacology, Pathology +7